Detalle Publicación

ARTÍCULO
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Autores: Garcia-Gomez, A. (Autor de correspondencia); Li, T.; de la Calle-Fabregat, C.; Rodriguez-Ubreva, J.; Ciudad, L.; Catala-Moll, F.; Godoy-Tena, G.; Martin-Sanchez, M.; San Segundo, L.; Muntion, S.; Morales Urteaga, Xabier; Ortiz de Solórzano Aurusa, Carlos; Oyarzabal Santamarina, Julen; San José Enériz, Edurne; Esteller, M.; Agirre, X.; Prosper Cardoso, Felipe; Garayoa, M.; Ballestar, E. (Autor de correspondencia)
Título de la revista: NATURE COMMUNICATIONS
ISSN: 2041-1723
Volumen: 12
Número: 1
Páginas: 421
Fecha de publicación: 2021
Lugar: WOS
Resumen:
Multiple myeloma (MM) progression and myeloma-associated bone disease (MBD) are highly dependent on bone marrow mesenchymal stromal cells (MSCs). MM-MSCs exhibit abnormal transcriptomes, suggesting the involvement of epigenetic mechanisms governing their tumor-promoting functions and prolonged osteoblast suppression. Here, we identify widespread DNA methylation alterations of bone marrow-isolated MSCs from distinct MM stages, particularly in Homeobox genes involved in osteogenic differentiation that associate with their aberrant expression. Moreover, these DNA methylation changes are recapitulated in vitro by exposing MSCs from healthy individuals to MM cells. Pharmacological targeting of DNMTs and G9a with dual inhibitor CM-272 reverts the expression of hypermethylated osteogenic regulators and promotes osteoblast differentiation of myeloma MSCs. Most importantly, CM-272 treatment prevents tumor-associated bone loss and reduces tumor burden in a murine myeloma model. Our results demonstrate that epigenetic aberrancies mediate the impairment of bone formation in MM, and its targeting by CM-272 is able to reverse MBD. Mesenchymal stromal cells (MSCs) have been shown to support multiple myeloma (MM) development. Here, MSCs isolated from the bone marrow of MM patients are shown to have altered DNA methylation patterns and a methyltransferase inhibitor reverts MM-associated bone loss and reduces tumour burden in MM murine models.